Industry
Biotechnology
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 11:57 am
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 2:57 pm
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 3:58 pm
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 7:44 pm
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 2:19 pm
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 1:25 pm
Portfolio Pulse from Benzinga Newsdesk
February 27, 2024 | 11:42 am
Portfolio Pulse from Benzinga Newsdesk
February 23, 2024 | 10:50 am
Portfolio Pulse from Benzinga Newsdesk
February 12, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
January 08, 2024 | 11:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.